H IV-1 (HIV), the causative agent of AIDS, represents a formidable global challenge, with the development of an effective vaccine being of paramount importance (1) (2) (3) (4) . Rapid progress in this area has been hindered in part by lack of a widely available small animal model for HIV entry. Currently available animal models include nonhuman primates and immunodeficient humanized mice, neither of which is readily available or amenable to genetic modifications (5, 6) .
Some viral pathogens exhibit a narrow host range, one of those being HIV. HIV's entry into target cells is mediated by binding of its trimeric envelope spike (gp160) to human CD4 (hCD4) (7) and subsequently to a coreceptor such as human CXCR4 (8) or human CCR5 (hCCR5) (9) (10) (11) . hCCR5 is of particular interest because it seems to be the primary coreceptor used for transmission (12, 13) , as evidenced by the finding that homozygous deletion in the CCR5 allele confers resistance against HIV-1 acquisition (14, 15) and can also lead to long-term control of HIV after stem cell transplantation (16) . Finally, HeLa cells and other HIV-resistant cells, including mouse cells, support viral entry when they are engineered to express hCD4/hCCR5/ hCXCR4 (17) (18) (19) .
Here, we describe a hCCR5-and hCD4-expressing luciferase reporter mouse that can be used to measure HIV pseudovirus entry and antibody-mediated protection against initial infection in vivo.
Results hCCR5-2A-hCD4 Construct. To overcome HIV's host-restriction at the level of viral entry, we coexpressed hCCR5 and hCD4 on a single poly-protein transcript separated by a ribosomal skip 2A peptide sequence (hCCR5-2A-hCD4) (Fig. 1A) (20) . Coexpression of hCCR5 and hCD4 was verified in transfected HEK293T cells (293T hCCR5-2A-hCD4 ) by flow cytometry (Fig. 1B) . The ability of these proteins to support viral entry was confirmed by infection of 293T hCCR5-2A-hCD4 with an HIV YU-2 pseudotyped lentivirus encoding GFP (Fig. 1C) . We conclude that the hCCR5-2A-hCD4 mRNA supports cell surface expression of the two proteins that restrict HIV entry into mammalian cells.
Adenoviral Delivery of hCCR5-2A-hCD4. Recombinant adenoviruses provide an established tool for efficient gene delivery and expression (21, 22) . To express high levels of the factors that restrict HIV entry in vivo, we used a recombinant human adenovirus (AdV) serotype 5 encoding hCCR5-2A-hCD4 under control of the CMV promoter (AdV-hCCR5-2A-hCD4) (21, 22) ( Fig. 2A) . AdV serotype 5 targets the liver after i.v. injection (23) (24) (25) (26) . We confirmed that i.v. administration of this vector resulted in hepatic expression of both hCD4 and hCCR5, as measured by fluorescence microscopy (Fig. 2B) . On the basis of immune fluorescence, we estimate that 30-40% of the cells in the liver express hCD4 and hCCR5.
In Vivo Infection with HIV YU-2 -Pseudotyped Lentivirus. To determine whether hCCR5-and hCD4-expressing mice can be used to measure HIV entry in vivo, we transduced mice that carry an inducible loxP-STOP-loxP luciferase reporter [Gt(ROSA) 26Sor tm1(Luc)Kaelin ] (27, 28) with AdV-hCCR5-2A-hCD4 (HIV-LUC AdV mice). One day later, HIV-LUC AdV mice were challenged i.v. with gp160 YU-2 -pseudotyped lentivirus (HIV YU-2 ) encoding Cre recombinase (Fig. 3A) . Productive viral uptake by hCCR5-2A-hCD4 expressing cells would result in the expression of Cre recombinase capable of excising the transcriptional stop element and consequently inducing luciferase expression. Bioluminescence activity, imaged in an optical luminometer (IVIS; Caliper Life Sciences), increased longitudinally and peaked between day 4 and 5 after i.v. pseudovirus injection into HIV-LUC AdV mice ( Fig. 3 B and C) . Despite a limited dynamic range and variation by as much as one order of magnitude between mice, there was a highly significant difference between experimental and control groups (P < 0.0001; Fig. 3D ). Taken together, the data indicate that HIV pseudovirus entry can be measured quantitatively in living mice.
Neutralizing Human Anti-HIV Monoclonal Antibodies Mediate
Protection in HIV-LUC AdV Mice. Antibodies are key components of most protective vaccines (29, 30) and thus are thought to be essential for protection against HIV infection. In support of this idea, passive administration of potent broadly neutralizing monoclonal antibodies can provide sterilizing immunity against simian/HIV (SHIV) infection in macaques (31) (32) (33) (34) (35) , and they seem to delay HIV rebound in humans (36, 37) . In addition, plasma concentration of anti-HIV IgG antibodies specific for the V1V2 loop region was inversely correlated with infection risk in the recent RV144 vaccine trial (38, 39) . However, the mechanisms that mediate the protective effects in RV144 are poorly understood, as exemplified by the finding that the vaccine assessed in the RV144 trial did not elicit broadly neutralizing antibodies (38) (39) (40) .
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G54W (41), 3BNC117 (42), 3BNC60 (42), VRC01 (43) , and b12 (44) all target the CD4 binding site, whereas PG16 (45) targets the V1/V2 loop region. These antibodies have varying levels of neutralizing activity (IC 50 ) in the TZM-bl cell assay against HIV YU-2 in vitro, ranging from 0.01 to 2.30 μg/mL (Fig. 4A ). Antibodies were administered individually at doses ranging from 1 μg to 200 μg s.c. 1 d before challenge with HIV YU-2 , and luciferase expression was measured 4 d later. Serum antibody levels determined at the time of pseudovirus injection varied among the selected monoclonal antibodies. For example, high levels were achieved after 3BNC117 injection, whereas antibody concentrations for NIH45-46 G54W were fourfold lower (Fig. 4B ). The different serum antibody levels are in keeping with the halflife of these antibodies, with 3BNC117 having t 1/2 = 48.6 h and NIH45-46 G54W having t 1/2 = 24.1 h after i.v. injection (Fig. S1 ).
In contrast to the HIV neutralizing antibodies that blocked entry with varying degrees of efficacy, an isotype control antibody (mGO53) (46) had no significant effect on entry compared with the PBS control ( Fig. 4 C and D). Fifty percent inhibition of entry was achieved after injection of 100-200 μg of VRC01 or PG16 or b12, whereas the same level of inhibition was obtained with as little as 4-6 μg of 3BNC117 or 3BNC60 or NIH45-46 G54W . For 3BNC117 and 3BNC60 this equals a serum concentration of ∼1 μg/mL, which is 100 times greater than the in vitro IC 50 (Fig. 4B) . We conclude that the ability of antibodies to inhibit HIV entry in vivo can be measured directly in HIV-LUC AdV mice.
Antibody Fc Involvement in Entry Inhibition. Neutralizing antibodies can protect against HIV infection in vitro in the absence of innate effector cells or complement (47) (48) (49) . However, the mechanisms by which they mediate protection against HIV in vivo are poorly understood. Complement seems to be essential in antibody-mediated postexposure protection in hu-SCID mice (50), whereas Fc receptors but not complement are important in antibody-mediated preexposure protection in macaques (51), but neither study resolves the question of whether antibodies protect from entry by direct viral clearance or by mediating clearance of infected cells or a combination of both.
To examine the role of antibody effector functions in protection against HIV entry we introduced mutations (G236R/ L328R) into the antibody Fc domain that eliminated binding to mFcγRs and complement ( Fig. S2 ) but did not alter antibody binding to the HIV envelope protein or neutralizing activity in vitro (Fig. S3 A-C and Tables S1 and S2) (52) . Dose-response experiments were performed to compare the in vivo activity of 3BNC60 GR/LR , 3BNC117 GR/LR , and VRC01 GR/LR to WT controls. GR/LR mutant and WT forms of the individual antibodies were present at similar serum concentrations at the time of pseudovirus injection (Fig. S3D) . Mutant 3BNC60 GR/LR and 3BNC117 GR/LR showed decreased activity at doses of 20 μg of injected antibody compared with the WT form (P = 0.0027 and P = 0.0044, respectively; Fig. 4E ). Although statistically significant, these differences were small and not found at higher or lower doses of 3BNC60 or 3BNC117 or at any tested dose of VRC01. Thus, although Fc effector function seems to make a contribution to the inhibition of HIV entry, additional studies will be necessary to fully evaluate this component.
Nonneutralizing Antibodies in Entry Inhibition. Although plasma concentration of anti-HIV IgG specific for the V1V2 loop region was inversely correlated with infection risk in the recent RV144 vaccine trial, broadly neutralizing antibodies were not found (38, 39) . Whether nonneutralizing monoclonal antibodies can mediate protection in vivo remains controversial (53) . For example, b6, a phage-derived monoclonal anti-HIV antibody with limited in vitro activity showed little or no protection against vaginal SHIV challenge in macaques (54) . However, the macaque experiments were performed on a relatively small number of subjects compared with the RV144 trial and may not have been sufficiently powered to detect effects of the magnitude found in the trial (38, 54) . To investigate whether nonneutralizing monoclonal antibodies can reduce viral entry, we selected two antibodies that bind to the HIV YU-2 trimer expressed as soluble protein (55) but that do not reach an IC 50 against HIV YU-2 at concentrations of up to 50 μg/mL in vitro: 1-79 targets the V3 loop (55), and 1-74 recognizes an epitope in proximity to the CD4 binding site (55) . Both of these antibodies were tested for their ability to block entry in vivo by injecting mice with 200 μg as described above. Neither reduced entry significantly compared with the isotype control (P = 0.1848 and P = 0.0830, respectively; Fig. 4F ). When testing 1-79 and 1-74 for binding to the HIV YU-2 trimer expressed on the surface of 293T cells, we found that their binding is relatively weak compared with the neutralizing antibodies examined above (Fig. 4G) . Thus, antibodies that bind weakly to the HIV trimer and do not neutralize the virus in the TZM-bl assay seem to have little or no effect reducing HIV entry in vivo. Additional studies with antibodies such as those derived from the RV144 trial will be necessary to fully evaluate the contribution of nonneutralizing antibodies in entry inhibition.
Discussion
Basic understanding of the humoral immune response to HIV has advanced significantly over the last several years. Antibody cloning experiments have revealed that humans can develop potent and broadly active serologic activity to the HIV trimer by producing combinations of antibodies to many different epitopes (55, 56) , or by producing unique monoclonal antibodies to specific target sites, such as the CD4 binding site (42, 57) . Moreover, broadly neutralizing human monoclonal antibodies can prevent chimeric SHIV infection in nonhuman primate models (31) (32) (33) (34) (35) , and antibodies seem to be the only correlate of protection in the recent RV144 vaccine trial (38, 39) .
However, progress toward an effective antibody-based vaccine has been elusive. One of the significant challenges in this area of research has been the development of adequate animal models to test vaccines or to study the mechanisms of action of broadly neutralizing antibodies. In vitro assays for antibody neutralization such as the TZM-bl assay, which is a reproducible and reliable assay for neutralizing antibody activity, do not take into account Fc-mediated antibody effector function or bioavailability (18) . Moreover, antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated viral inhibition (ADCVI) assays, which are commonly used to try to measure effector function in vitro, are far more difficult to reproduce and standardize than the TZM-bl assay and are limited in that they include only a fraction of the effector cells that participate in antibody-mediated effector activity in vivo (49) .
Although they cannot be infected with HIV, rhesus macaques are the current gold standard for testing vaccines because they can be challenged with simian immunodeficiency virus (SIV) (58), or with chimeric SHIV (59). However, there are a number of important issues with these models, including the fact that SIV and SHIV do not produce the same disease in rhesus macaques as HIV in humans, nor are they identical to HIV in terms of the requirements for effective vaccination (60) . In addition, there is the problem of limited availability of macaques, enormous expense, inability to control for genetic heterogeneity, and finally ethical considerations.
Humanized mice (hu-mice) containing human cell-and, in some cases, tissue-transplants represent an alternative to macaques (reviewed in ref. 61) . This model may be particularly useful for pharmacologic studies of anti-HIV drugs (62) and passive immunization (63) , but it is limited in some important ways. Adaptive immune responses, and in particular antibodymediated immune responses to HIV, are not optimal in these mice, and therefore they are not amenable to studies that require vaccination (64) (65) (66) (67) . Equally important, genetic experiments are not possible in chimeric mice containing mouse and human cells.
In contrast to hu-mice, the HIV-LUC AdV mouse model is fully immunocompetent, providing a platform for combined immunization and challenge studies using the i.v. route of infection. This route of exposure, which occurs primarily among i.v. drug users, represents a growing global health challenge (68) . Additional advantages of the HIV-LUC AdV mice include the use of replication-deficient pseudovirus (18) as opposed to infectious virus and the possibility of genetic modifications. However, HIV-LUC AdV mice express hCCR5/hCD4 in hepatocytes, a nonphysiological target of HIV, owing to preferential hepatic expression of the Coxsackie and adenovirus receptor (CAR) in mice (69, 70) . Although infection of other cell types might be achieved, it would require transgenic expression of human CAR (hCAR); for example, under control of the ubiquitin promoter using the available hCAR transgenic mouse (71) or targeting hCAR expression to specific cell types using tissue-specific promoters (72) . Alternatively, if expression is high enough, transgenic mice expressing hCCR5/hCD4 under a T cell-specific promoter (19) could be used after breeding to Gt(ROSA) 26Sor tm1(Luc)Kaelin reporter mice. Still another alternative that could be used in combination with humanized mice would be infectious molecular clones that stably express luciferase (Env-IMC-LucR) (73) .
Previous experiments in hu-mice and macaques showed that broadly neutralizing antibodies can interfere with HIV infection in vivo (50, 51) . However, these experiments could not distinguish whether protection from infection was due to the effects of antibodies on infected cells or to blocking HIV entry directly, or a combination thereof. The availability of HIV-LUC AdV mice allowed for quantitative assessment of potent broadly neutralizing antibodies in vivo and revealed that the antibodies block viral entry directly because this model does not support HIV envelope expression on the surface of infected cells. This means that ADCC would not influence viral control in this system; however, other effector mechanisms, such as Fc-dependent viral uptake by Kupffer cells or other phagocytes, could play a role in viral clearance (74) .
A large number of antibodies were compared directly using pseudotyped virus expressing the envelope of HIV YU-2 , a difficultto-neutralize tier 2 virus. The HIV-LUC AdV mouse model made it possible to perform dose-response experiments with a significant number of mice (220 in total), something that would be very difficult to achieve in macaques, for which the number of well-characterized SHIV envelopes and experimental animals are very limited. We find that neutralizing activity is related to both the in vitro activity in TZM-bl assays and to bioavailability in vivo. For example, VRC01 did not perform as well as 3BNC60 after s.c. injection of equivalent doses, likely owing to the lower bioavailability of VRC01 and the weaker in vitro neutralizing potency. Conversely, NIH45-46 G54W , which had equal potency in vitro but lower bioavailability than 3BNC117, was similar in its ability to the latter in blocking infection in HIV-LUC AdV mice. The low bioavailability of NIH45-46 G54W is probably related to its high levels of polyreactivity, as evidenced by its binding to mock-transfected HEK293T cells (Fig. 4G) . Finally, our results suggest an involvement of Fc effector functions in entry protection, and therefore our experiments are in agreement with the macaque SHIV model (51) but extend those findings by revealing the importance of antibody dose on the effect of the antibody Fc region on protection against HIV in vivo. Additional insights might also be gained by evaluation of antibodies targeting glycan residues (75) or antibodies targeting the membrane-proximal external region (74) .
In conclusion, HIV-LUC AdV mice resemble the TZM-bl assay system in that they serve as an assay for HIV entry into heterologous cells, with the important additional dimension of doing so in vivo where the effects of antibody effector functions and bioavailability can be measured. AdV Constructs. hCD4 and hCCR5 were PCR-amplified from pT4B (76) and pc. CCR-5 (9, 77) respectively.
Materials and Methods
hCD4 forward: GTCGACGCCACCATGAACCGGGGAGTCCCTTT hCD4 reverse: GCGGCCGCCATTCATTCATTCAAATGGGGCTACATGTCTT hCCR5 forward: GTCGACGCCACCATGGATTATCAAGTGTCAAG hCCR5 reverse: GCGGCCGCCATTCATTCATTCACAAGCCCACAGATATTT hCCR5 and hCD4 were linked by the ribosomal skip T2A peptide sequence (GSGEGRGSLLTCGDVEENPGP) (20) and inserted into pMX-IRES-mCherry (78) using EcoRI and BamHI sites. The adenoviral construct expressing hCCR5-2A-hCD4 was created using the AdEasy Adenoviral Vector System (Agilent Technologies) according to the manufacturer's instructions. All plasmid constructs were verified by DNA sequencing.
A detailed description of flow cytometry, production of recombinant AdVs, HIV pseudovirus production and in vivo infection, histological detection of hCCR5 and hCD4, serum antibody ELISA, bioluminescence imaging, neutralization assays, recombinant protein expression and purification, sitedirected mutagenesis, gp140 ELISA, surface plasmon resonance, C1q binding and C3 fixation assays, mAb binding to cell surface gp160, immune complex binding assay, and statistical analysis are provided in SI Materials and Methods.
